Roivant Sciences officer proposes $6.73M share sale

The shares are identified as performance stock units acquired from the issuer for services rendered on November 10, 2026.

Available on EDGAR 11/10/2026 - 04:25 PM EST Accepted by SEC EDGAR 11/10/2026 - 04:25 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Roivant Sciences Ltd. identifies Matthew Adam Gline, an officer and director, in a proposed sale of 164,136 common shares. The approximate sale date is November 10, 2026, and the aggregate market value is $6,729,576.00.

Key Figures

Common shares proposed for sale: 164,136 shares Aggregate market value: $6,729,576.00 Common shares outstanding: 724,561,460 shares

3 metrics

Common shares proposed for sale 164,136 shares Approximate sale date: November 10, 2026

Aggregate market value $6,729,576.00 For the proposed sale

Common shares outstanding 724,561,460 shares Listed as the number of shares or other units outstanding

Key Terms

Performance Stock Units, Aggregate Market Value, Number of Shares or Other Units Outstanding

3 terms

Performance Stock Units financial

"Nature of Acquisition Transaction: Performance Stock Units"

Performance stock units are a type of company award that grants employees shares of stock only if certain performance goals are met. They motivate employees to work toward specific company achievements, aligning their interests with those of shareholders. For investors, they can influence a company's future stock supply and reflect management’s confidence in reaching key targets.

Aggregate Market Value financial

"Aggregate Market Value: 6729576.00"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

Number of Shares or Other Units Outstanding financial

"Number of Shares or Other Units Outstanding"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ROIV shares did Matthew Adam Gline report for sale?

Matthew Adam Gline reported 164,136 common shares for sale, with an approximate sale date of November 10, 2026, and an aggregate market value of $6,729,576.00.

How did Matthew Adam Gline acquire the ROIV shares listed for sale?

The shares are identified as performance stock units acquired from Roivant Sciences Ltd. on November 10, 2026; the nature of payment is listed as services rendered.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001750094
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	ROIVANT SCIENCES LTD.
SEC File Number	001-40782
Address of Issuer	7th Floor 50 Broadway London UNITED KINGDOM SW1H 0DB
Phone	44 207 400 3347
Name of Person for Whose Account the Securities are To Be Sold	MATTHEW ADAM GLINE
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	164136	6729576.00	724561460	11/10/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/10/2026	Performance Stock Units	Issuer			164136	11/10/2026	Services Rendered

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	11/10/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Matthew Adam Gline
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)